B6E Stock Overview
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr23.84 |
| 52 Week High | kr26.46 |
| 52 Week Low | kr16.88 |
| Beta | 0.27 |
| 1 Month Change | 3.83% |
| 3 Month Change | -5.55% |
| 1 Year Change | 7.10% |
| 3 Year Change | 70.41% |
| 5 Year Change | 50.51% |
| Change since IPO | 100.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| B6E | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.6% | -0.2% | 0.5% |
| 1Y | 7.1% | -22.8% | 1.3% |
Return vs Industry: B6E exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: B6E exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| B6E volatility | |
|---|---|
| B6E Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B6E has not had significant price volatility in the past 3 months.
Volatility Over Time: B6E's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,772 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| B6E fundamental statistics | |
|---|---|
| Market cap | €8.17b |
| Earnings (TTM) | €183.41m |
| Revenue (TTM) | €1.98b |
44.5x
P/E Ratio4.1x
P/S RatioIs B6E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B6E income statement (TTM) | |
|---|---|
| Revenue | kr23.14b |
| Cost of Revenue | kr5.43b |
| Gross Profit | kr17.71b |
| Other Expenses | kr15.56b |
| Earnings | kr2.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 16, 2024
| Earnings per share (EPS) | 6.30 |
| Gross Margin | 76.52% |
| Net Profit Margin | 9.26% |
| Debt/Equity Ratio | 52.6% |
How did B6E perform over the long term?
See historical performance and comparison